Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801)

By sjmartinez • March 19, 2025

Othus M, Sharon E, Wu MC, Sondak VK, Ribas A, Patel SP. Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Clin Trials. 2025 Mar 18:17407745251321371. doi: 10.1177/17407745251321371. Epub ahead of print. PMID: 40099861.

Tags: Hematology/Oncology, neoadjuvant, Publications, Randomized comparison, tumor measurement schedule

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Davar D, Eroglu Z, Pérez CL, Di Pace B, Wang T, Yanamandra N, Ghosh S, Jansen K, Dhar A, Borgovan T, Waszak A, Ribas A.[...]

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, Di Pace B, Wang T, Zhang H, Ghosh S, Yanamandra N, Borgovan T,[...]

Risk Factors for Solid Organ Graft Failure and Death in Solid Organ Transplant Recipients Undergoing Hematopoietic Cell Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research (CIBMTR) and Organ Procurement and Transplantation Network (OPTN) Study

Gupta M, Schoettler ML, Orozco G, Brazauskas R, Bo-Subait S, Battiwalla M, Buchbinder D, Hamilton BK, Savani BN, Schoemans H, Sorror ML, Ahmed S, Badawy[...]